<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02758769</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-574</org_study_id>
    <nct_id>NCT02758769</nct_id>
  </id_info>
  <brief_title>Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings</brief_title>
  <official_title>Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      Examine the effectiveness and safety of the abatacept administration in biologic-naïve
      rheumatoid arthritis patients who have moderate disease activity despite treatments with
      conventional synthetic disease modified anti-rheumatic drugs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2015</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of achievement in simplified disease activity index (SDAI) remission after administration of abatacept</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of achievement in low disease activity by simplified disease activity index (SDAI).</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the percentage of disease activity category by simplified disease activity index(SDAI)</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the percentage of disease activity category by clinical disease activity index(CDAI)</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the percentage of disease activity category by disease activity score with 28 joint counts - erythrocyte sedimentation rate (DAS28-ESR)</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the percentage of disease activity category by disease activity score with 28 joint counts creactive protein (DAS28-CRP)</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in simplified disease activity index(SDAI)</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical disease activity index(CDAI)</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in disease activity score with 28 joint counts - erythrocyte sedimentation rate (DAS28-ESR)</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in disease activity score with 28 joint counts Creactive protein (DAS28-CRP)</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Anti-citrullinated protein antibodies (ACPA)</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rheumatoid factors (RF)</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization rate</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of occurrences of rheumatoid arthritis related surgery</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence rate of Abatacept treatment</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for discontinuation of Abatacept treatment</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Japanese Health Assessment Questionnaire</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in European Quality of Life 5 Dimension Questionnaire</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain visual analog scale</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in General visual analog scale</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PRO parameters defined in IORRA registry (JMAJ 2009 52 (1) 54-56)</measure>
    <time_frame>0 Months, 1 Month, 6 Months, 12 Months, 18 Months, 24 Months, 30 Months, 36 Months, 42 Months, 48 Months, 54 Months and 60 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>ORENCIA with Exposure</arm_group_label>
    <description>ORENCIA with Exposure</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ORENCIA Subcutaneous Injection</intervention_name>
    <arm_group_label>ORENCIA with Exposure</arm_group_label>
    <other_name>Abatacept</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with RA who meet the 2010 American College of Rheumatology / European League
             against Rheumatisms (ACR/EULAR) RA Classification Criteria

          -  Patients with RA with a moderate disease activity (SDAI: &gt; 11 and 26)

          -  Biologic-naive patients with treatment history csDMARDs

          -  Patients who meet the following criteria by hematological examination:

               -  Peripheral white blood cell count: 4,000/mm3

               -  Peripheral lymphocyte count: 1,000/mm3

               -  Blood β-D-glucan negative

          -  Patients who understand the investigator's explanation of study procedures and have
             given voluntary written consent to participate in this study

          -  Patients initiated with abatacept at per their physician's therapeutic decision

        Exclusion Criteria:

          -  Past history of hypersensitivity to the components of the abatacept preparation

          -  Disease complications from a comorbidity

          -  Active infectious disease

          -  Been judged by the investigator or the co-investigator as being inappropriate

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>1070052</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

